Tobacco smoking, harm reduction, and biomarkers

Journal of the National Cancer Institute

Volumn 94, Issue 19, 2002, Pages 1435-1444

  Shields, Peter G ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BIOLOGICAL MARKER; CARCINOGEN; CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE; TAR;

AGE; BEHAVIOR; CANCER CONTROL; CANCER RISK; CELL CULTURE; CIGARETTE SMOKING; CLINICAL STUDY; ENVIRONMENTAL EXPOSURE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETICS; IN VITRO STUDY; LUNG CANCER; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SAFETY; SEX DIFFERENCE; SMOKING CESSATION; SMOKING HABIT; THEORY;

EID: 0037009836     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.19.1435     Document Type: Review

References (146)

1. Institute of Medicine, Committee to Assess the Science Base for Tobacco Harm Reduction, Board on Health Promotion and Disease Prevention. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington (DC): National Academy Press; 2001.
2. Augustine A, Harris RE, Wynder EL. Compensation as a risk factor for lung cancer in smokers who switch from nonfilter to filter cigarettes. Am J Public Health 1989;79:188-91.
3. Stellman SD, Muscat JE, Hoffmann D, Wynder EL. Impact of filter cigarette smoking on lung cancer histology. Prev Med 1997;26:451-6.
4. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64.
5. National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and tobacco control [Monograph 13]. 2002.
6. Smith CJ, McKarns SC, Davis RA, Livingston SD, Bombick BR, Avalos JT, et al. Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutat Res 1996;361:1-9.
7. Perera FP. Molecular cancer epidemiology: a new tool in cancer prevention. J Natl Cancer Inst 1987;78:887-98.
8. Vineis P, Porta M. Causal thinking, biomarkers, and mechanisms of carcinogenesis. J Clin Epidemiol 1996;49:951-6.
9. Santella RM, Weston A, Perera FP, Trivers GE, Harris CC, Young TL, et al. Interlaboratory comparison of antisera and immunoassays for benzo [a]pyrene-diol-epoxide-I modified DNA. Carcinogenesis 1988;9:1265-9.
10. Farmer PB, Shuker DE. What is the significance of increases in background levels of carcinogen-derived protein and DNA adducts? Some considerations for incremental risk assessment. Mutat Res 1999;424: 275-86.
11. Prevost V, Shurker DE. Cigarette smoking and urinary 3-alkyladenine excretion in man. Chem Res Toxicol 1996;9:439-44.
12. U.S. Department of Health, Education and Welfare (DHEW). Smoking and health. A report of the Surgeon General. Washington (DC): 1988 DHEW Publ No. (PHS)79-50066. p. 5-11.
13. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: tobacco smoking. Vol. 38. Lyon (France): IARC; 1986.
14. Zang EA, Wynder EL. Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 1992;70:69-76.
15. La Vecchia C, Bidoli E, Barra S, D'Avanzo B, Negri E, Talamini R, et al. Type of cigarettes and cancers of the upper digestive and respiratory tract. Cancer Causes Control 1990;1:69-74.
16. Kaufman DW, Palmer JR, Rosenberg L, Stolley P, Warshauer E, Shapiro S. Tar content of cigarettes in relation to lung cancer. Am J Epidemiol 1989;129:703-11.
17. La Vecchia C, Liati P, Decarli A, Negrello I, Franceschi S. Tar yields of cigarettes and the risk of oesophageal cancer. Int J Cancer 1986;38:381-5.
18. Stellman SD, Garfinkel L. Lung cancer risk is proportional to cigarette tar yield: evidence from a prospective study. Prev Med 1989;18:518-25.
19. Wilcox HB, Schoenberg JB, Mason TJ, Bill JS, Stemhagen A. Smoking and lung cancer: risk as a function of cigarette tar content. Prev Med 1988;17:263-72.
20. Lubin JH, Blot WJ, Berrino F, Flamant R, Gillis CR, Kunze M, et al. Patterns of lung cancer risk according to type of cigarette smoked. Int J Cancer 1984;33:569-76.
21. Vutuc C, Kunze M. Tar yields of cigarettes and male lung cancer risk. J Natl Cancer Inst 1983;71:435-7.
22. Fischer S, Spiegelhalder B, Preussmann R. Influence of smoking parameters on the delivery of tobacco-specific nitrosamines in cigarette smoke - a contribution to relative risk evaluation. Carcinogenesis 1989; 10:1059-66.
23. Djordjevic MV, Stellman SD, Zang E. Doses of nicotine and lung carcinogens delivered to cigarette smokers. J Natl Cancer Inst 2000;92: 106-11.
24. Byrd GD, Davis RA, Caldwell WS, Robinson JH, deBethizy JD. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacology (Berl) 1998;139:291-9.
25. Byrd GD, Robinson JH, Caldwell WS, deBethizy JD. Comparison of measured and FTC-predicted nicotine uptake in smokers. Psychopharmacology (Berl) 1995;122:95-103.
26. Bridges RB, Humble JW, Turbek JA, Rehm SR. Smoking history, cigarette yield and smoking behavior as determinants of smoke exposure. Eur J Respir Dis Suppl 1986;146:129-37.
27. Herning RI, Jones RT, Benowitz NL, Mines AH. How a cigarette is smoked determines blood nicotine levels. Clin Pharmacol Ther 1983;33: 84-90.
28. Gritz ER, Rose JE, Jarvik ME. Regulation of tobacco smoke intake with paced cigarette presentation. Pharmacol Biochem Behav 1983;18:457-62.
29. Kolonen S, Tuomisto J, Puustinen P, Airaksinen MM. Puffing behavior during the smoking of a single cigarette in a naturalistic environment. Pharmacol Biochem Behav 1992;41:701-6.
30. Hofer I, Nil R, Wyss F, Battig K. The contributions of cigarette yield, consumption, inhalation and puffing behaviour to the prediction of smoke exposure. Clin Investig 1992;70:343-51.
31. Benowitz NL, Jacob P 3rd, Kozlowski LT, Yu L. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med 1986;315:1310-3.
32. Benowitz NL, Jacob P 3rd, Yu L, Talcott R, Hall S, Jones RT. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. JAMA 1986;256:241-6.
33. Benowitz NL, Zevin S, Jacob P 3rd. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 1998;287:958-62.
34. Hill P, Marquardt H. Plasma and urine changes after smoking different brands of cigarettes. Clin Pharmacol Ther 1980;27:652-8.
35. Ebert RV, McNabb ME, McCusker KT, Snow SL. Amount of nicotine and carbon monoxide inhaled by smokers of low-tar, low-nicotine cigarettes. JAMA 1983;250:2840-2.
36. Benowitz NL, Hall SM, Herning RI, Jacob P 3rd, Jones RT, Osman AL. Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med 1983;309:139-42.
37. Bridges RB, Combs JG, Humble JW, Turbek JA, Rehm SR, Haley NJ. Puffing topography as a determinant of smoke exposure. Pharmacol Biochem Behav 1990;37:29-39.
38. Law MR, Morris JK, Watt HC, Wald NJ. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. Br J Cancer 1997;75:1690-3.
39. Bono R, Russo R, Arossa W, Scursatone E, Gilli G. Involuntary exposure to tobacco smoke in adolescents: urinary cotinine and environmental factors. Arch Environ Health 1996;51:127-31.
40. Benowitz NL. Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect 1999;107 Suppl 2:349-55.
41. Crawford FG, Mayer J, Santella RM, Cooper TB, Ottman R, Tsai WY, et al. Biomarkers of environmental tobacco smoke in preschool children and their mothers. J Natl Cancer Inst 1994;86:1398-402.
42. Jacob P 3rd, Yu L, Shulgin AT, Benowitz NL. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health 1999;89:731-6.
43. Lodovici M, Akpan V, Giovannini L, Migliani F, Dolara P. Benzo[a]pyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs. Chem Biol Interact 1998; 116:199-212.
44. Carmella SG, Akerkar SA, Richie JP Jr, Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995;4:635-42.
45. Carmella SG, Akerkar S, Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res 1993;53:721-4.
46. Atawodi SE, Lea S, Nyberg F, Mukeria A, Constantinescu V, Ahrens W, et al. 4-Hydroxy-1-(3-pyridyl)-1-butanone-hemoglobin adducts; as biomarkers of exposure to tobacco smoke: validation of a method to be used in multicenter studies. Cancer Epidemiol Biomarkers Prev 1998;7: 817-21.
47. Yamasaki E, Ames BN. Concentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proc Natl Acad Sci U S A 1977;74:3555-9.
48. Jaffe RL, Nicholson WJ, Garro AJ. Urinary mutagen levels in smokers. Cancer Lett 1983;20:37-42.
49. Mohtashamipur E, Norpoth K, Lieder F. Isolation of frameshift mutagens from smokers' urine: experiences with three concentration methods. Carcinogenesis 1985;6:783-8.
50. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
51. Lee CK, Brown BG, Reed EA, Coggins CR, Doolittle DJ, Hayes AW. Ninety-day inhalation study in rats, using aged and diluted sidestream smoke from a reference cigarette: DNA adducts and alveolar macrophage cytogenetics. Fundam Appl. Toxicol 1993;20:393-401.
52. Wang LE, Bondy ML, de Andrade M, Strom SS, Wang X, Sigurdson A, et al. Gender difference in smoking effect on chromosome sensitivity to gamma radiation in a healthy population. Radiat Res 2000;154: 20-7.
53. La DK, Swenberg JA. DNA adducts: biological markers of exposure and potential applications to risk assessment. Mutat Res 1996;365:129-46.
54. Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, et al. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the Physicians Health Study. Cancer Res 2001;61: 6708-12.
55. Nakayama J, Yuspa SH, Poirier MC Benzo(a)pyrene-DNA adduct formation and removal in mouse epidermis in vivo and in vitro: relationship of DNA binding to initiation of skin carcinogenesis. Cancer Res 1984; 44:4087-95.
56. Ashurst SW, Cohen GM, Nesnow S, DiGiovanni J, Slaga TJ. Formation of benzo(a)pyrene/DNA adducts and their relationship to tumor initiation in mouse epidermis. Cancer Res 1983;43:1024-9.
57. Pelkonen O, Vahakangas K, Nebert DW. Binding of polycyclic aromatic hydrocarbons to DNA: comparison with mutagenesis and tumorigenesis. J Toxicol Environ Health 1980;6:1009-20.
58. Dunn BP, Vedal S, San RH, Kwan WF, Nelems; B, Enarson DA, et al. DNA adducts in bronchial biopsies. Int J Cancer 1991;48:485-92.
59. Van Schooten FJ, Hillebrand MJ, Van Leeuwen FE, Lutgerink JT, van Zandwijk N, Jansen HM, et al. Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. Carcinogenesis 1990;11: 1677-81.
60. Tang D, Santella RM, Blackwood AM, Young TL, Mayer J, Jaretzki A, et al. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol Biomarkers Prev 1995;4:341-6.
61. Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, et al. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1998;7:341-6.
62. Schoket B, Phillips DH, Kostic S, Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis 1998;19:841-6.
63. Wiencke JK, Kelsey KT, Varkonyi A, Semey K, Wain JC, Mark E, et al. Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res 1995;55:4910-4.
64. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 1988; 336:790-2.
65. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994;369:154-6.
66. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995;87:902-7.
67. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 1997;18:1285-9.
68. Rojas M, Alexandrov K, Cascorbi I, Brockmoller J, Likhachev A, Pozharisski K, et al. High benz[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTMI*0/*0 genotypes. Pharmacogenetics 1998;8:109-18.
69. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995;55:5230-7.
70. Stern SJ, Degawa M, Martin MV, Guengerich FP, Kaderlik RK, Ilett KF, et al. Metabolic activation, DNA adducts, and H-ras mutations in human neoplastic and non-neoplastic laryngeal tissue. J Cell Biochem Suppl 1993;17F:129-37.
71. Grinberg-Funes RA, Singh VN, Perera FP, Bell DA, Young TL, Dickey C, et al. Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathione-S-transferase M1 genotype. Carcinogenesis 1994;15:2449-54.
72. Pastorelli R, Guanci M, Cerri A, Negri E, La Vecchia C, Fumagalli F, et al. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev 1998;7:703-9.
73. Wiencke JK, Thurston SW, Kelsey KT, Varkonyi A, Wain JC, Mark EJ, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst 1999;91:614-9.
74. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994;7:91-7.
75. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993;82:3163-9.
76. 32P-postlabeling analysis of 7-methylguanine in human bronchial and lymphocyte DNA. Carcinogenesis 1993;14:151-4.
77. Bryant MS, Skipper PL, Tannenbaum SR, Maclure M. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res 1987;47:602-8.
78. Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc Natl Acad Sci U S A 1988;85:9788-91.
79. 32P-postlabeling analysis. Carcinogenesis 1990;11:205-11.
80. Mooney LA, Santella RM, Covey L, Jeffrey AM, Bigbee W, Randall MC, et al. Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation. Cancer Epidemiol Biomarkers Prev 1995;4:627-34.
81. 32P-postlabeling assay. J Natl Cancer Inst 1989;81:341-7.
82. Rothman N, Poirier MC, Baser ME, Hansen JA, Gentile C, Bowman ED, et al. Formation of polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells during consumption of charcoal-broiled beef. Carcinogenesis 1990;11:1241-3.
83. Ramsey MJ, Moore DH, Briner JF, Lee DA, Olsen L, Senft JR, et al. The effects of age and lifestyle factors on the accumulation of cytogenetic damage as measured by chromosome painting. Mutat Res 1995;338:95-106.
84. Bender MA, Awa AA, Brooks AL, Evans HJ, Groer PG, Littlefield LG, et al. Current status of cytogenetic procedures to detect and quantify previous exposures to radiation. Mutat Res 1988;196:103-59.
85. Obe G, Vogt HJ, Madle S, Fahning A, Heller WD. Double-blind study on the effect of cigarette smoking on the chromosomes of human peripheral blood lymphocytes in vivo. Mutat Res 1982;92:309-19.
86. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998;32:110-6.
87. Speit G, Hartmann A. The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol 1999;113:203-12.
88. Poli P, Buschini A, Spaggiari A, Rizzoli V, Carlo-Stella C, Rossi C. DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay. Toxicol Lett 1999;108:267-76.
89. Pressl S, Edwards A, Stephan G. The influence of age, sex and smoking habits on the background level of fish-detected translocations. Mutat Res 1999;442:89-95.
90. van Diemen PC, Maasdam D, Vermeulen S, Darroudi F, Natarajan AT. Influence of smoking habits on the frequencies of structural and numerical chromosomal aberrations in human peripheral blood lymphocytes using the fluorescence in situ hybridization (FISH) technique. Mutagenesis 1995;10:487-95.
91. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-62.
92. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994;264:1317-9.
93. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278:1054-9.
94. Belinsky SA, Nikula. KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
95. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017-9.
96. Liu CS, Kao SH, Wei YH. Smoking-associated mitochondrial DNA mutations in human hair follicles. Environ Mol Mutagen 1997;30:47-55.
97. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci U S A 1993;90:1614-8.
98. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 1994;91:8910-4.
99. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
100. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973;289:934-7.
101. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982;42:5030-7.
102. Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996;17:2279-84.
103. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang ZF, Tobi H, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530-5.
104. Cloos J, Braakhuis BJ, Steen I, Copper MP, de Vries N, Nauta JJ, et al. Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 1994;56:816-9.
105. Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidermiol Biomarkers Prev 1995;4:99-103.
106. Li D, Wang M, Cheng L, Spitz MR, Hittelman WN, Wei Q. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 1996;56:3638-41.
107. Wei Q, Gu J, Cheng L, Bondy ML, Jiang H, Hong WK, et al. Benzo(a) pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Res 1996;56:3975-9.
108. Hall J, Bresil H, Donato F, Wild CP, Loktionova NA, Kazanova OI, et al. Alkylation and oxidative-DNA damage repair activity in blood leukocytes of smokers and non-smokers. Int J Cancer 1993;54:728-33.
109. Slupphaug G, Lettrem I, Myrnes B, Krokan HE. Expression of O6-methylguanine-DNA methyltransferase and uracil-DNA glycosylase in human placentae from smokers and non-smokers. Carcinogenesis 1992;13:1769-73.
110. Drin I, Schoket B, Kostic S, Vincze I. Smoking-related increase in O6-alkylguanine-DNA alkyltransferase activity in human lung tissue. Carcinogenesis 1994;15:1535-9.
111. Shields PG. Epidemiology of tobacco carcinogenesis. Curr Oncol Rep 2000;2:257-62.
112. Perera FP. Environment and cancer: who are susceptible? Science 1997;278:1068-73.
113. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25.
114. Brockmoller J, Cascorbi I, Kerb R, Sachse C, Roots I. Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett 1998;102-103:173-83.
115. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics 1999;9:103-11.
116. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
117. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997;96:2128-36.
118. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 1999;81:44-8.
119. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 1998;7:19-23.
120. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993;85:1159-64.
121. Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 1997;6:1075-80.
122. Bishop JM. The molecular genetics of cancer. Science 1987;235:305-11.
123. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6:87-92.
124. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995;5:199-206.
125. Yu MC, Ross RK, Chan KK, Henderson BE, Skipper PL, Tannenbaum SR, et al. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and non-smokers. Cancer Epidemiol Biomarkers Prev 1995;4:861-4.
126. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996;56:72-6.
127. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, et al. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 1997;17:583-7.
128. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, et al. p53-mutations in lung tumors. Relationship to putative susceptibility markers for cancer. Cancer Res 1994;54:1551-5.
129. Lazarus P, Sheikh SN, Ren Q, Schantz SP, Stern JC, Richie JP Jr, et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 1998;19:509-14.
130. Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 1998;400:15-24.
131. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001;22:593-7.
132. Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:119-23.
133. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
134. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001;92:562-7.
135. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:125-31.
136. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
137. Carmelli D, Swan GE, Robinette D, Fabsitz R. Genetic influence on smoking - a study of male twins. N Engl J Med 1992;327:829-33.
138. Heath AC, Cates R, Martin NG, Meyer J, Hewitt JK, Neale MC, et al. Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. J Subst Abuse 1993;5:221-46.
139. Heath AC, Martin NG. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addict Behav 1993;18:19-34.
140. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, et al. Dopamine D4 receptors and the risk of cigarette smoking in A frican Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998;7:453-8.
141. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, Fitch RJ, et al. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994;42:257-60.
142. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;6:73-9.
143. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, et al. A case-control study of the doparmine D2 receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998;90:358-63.
144. Gilbert DG, Gilbert BO. Personality, psychopathology, and nicotine response as mediators of the genetics of smoking. Behav Genet 1995;25:133-47.
145. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976;2:1525-36.
146. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993;85:457-64.